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Neuroblastoma is one of the commonest and deadliest solid tumours of childhood, and is thought to result from
disrupted differentiation of the developing sympathoadrenergic lineage of the neural crest. Neuroblastoma
exhibits intra- and intertumoural heterogeneity, with high risk tumours characterised by poor differentiation, which
can be attributable to MYCN-mediated repression of genes involved in neuronal differentiation. MYCN is known to
co-operate with oncogenic signalling pathways such as Alk, Akt and MEK/ERK signalling, and, together with c-
MYC has been shown to be activated by Wnt signalling in various tissues. However, our previous work
demonstrated that Wnt3a/Rspo2 treatment of some neuroblastoma cell lines can, paradoxically, decrease c-MYC
and MYCN proteins. This prompted us to define the neuroblastoma-specific Wnt3a/Rspo2-driven transcriptome
using RNA sequencing, and characterise the accompanying changes in cell biology. Here we report the
identification of ninety Wnt target genes, and show that Wnt signalling is upstream of numerous transcription
factors and signalling pathways in neuroblastoma. Using live-cell imaging, we show that Wnt signalling can drive
differentiation of SK-N-BE(2)-C and SH-SY5Y cell-lines, but, conversely, proliferation of SK-N-AS cells. We show
that cell-lines that differentiate show induction of pro-differentiation BMP4 and EPAS1 proteins, which is not
apparent in the SK-N-AS cells. In contrast, SK-N-AS cells show increased CCND1, phosphorylated RB and E2F1 in
response to Wnt3a/Rspo2, consistent with their proliferative response, and these proteins are not increased in
differentiating lines. By meta-analysis of the expression of our 90 genes in primary tumour gene expression
databases, we demonstrate discrete expression patterns of our Wnt genes in patient cohorts with different
prognosis. Furthermore our analysis reveals interconnectivity within subsets of our Wnt genes, with one subset
comprised of novel putative drivers of neuronal differentiation repressed by MYCN. Assessment of β-catenin
immunohistochemistry shows high levels of β-catenin in tumours with better differentiation, further supporting a
role for canonical Wnt signalling in neuroblastoma differentiation.
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Neuroblastoma is responsible for approximately 15% of paediatric
cancer deaths, with about 40% of patients considered to be high-risk
cases with very poor prognosis [1,2]. Neuroblastoma is a biologically
and clinically heterogeneous cancer arising from the sympathoadre-
nergic lineage of the neural crest [3]. Very recently, studies have
demonstrated that tumours and cell-lines derived from them exhibit
cellular heterogeneity based on enhancer usage and core regulatory
transcriptional circuits [4,5]. The paradigmatic mechanism for
disrupted differentiation in neuroblastoma is contingent on ampli-
fication of theMYCN proto-oncogene [6], with high levels of MYCN
protein leading to direct repression of genes necessary for terminal
differentiation in the sympathetic nervous system [7,8]. As well as
MYCN amplification (MNA), high risk neuroblastomas have also
been shown to elevate telomerase reverse transcriptase (TERT)
expression through deregulatory genomic rearrangements [9,10].
Kinase pathways are also deregulated in neuroblastoma, including
activating mutations of ALK [11], increased Akt signalling in stage 3
and 4 neuroblastoma [12], and relapsing neuroblastomas displaying
mutations in the Ras-MAPK pathway [13,14].
Another oncogenic pathway reported to be involved in neuroblas-
toma, as well as many other cancers is canonical Wnt signalling. Here
signalling is mediated by secreted Wnt ligands that are bound by
membrane receptor complexes including Frizzled proteins and LRP5/
6. This then triggers inactivation of a cytoplasmic “destruction
complex” that limits cytoplasmic β-catenin, permitting its stabiliza-
tion and nuclear availability. The TCF/Lef family of transcription
factors are then able to utilise β-catenin as a transcriptional co-
activator, and instigate target gene expression [15]. Amplification of
canonical Wnt signalling can be achieved through the participation of
another set of receptors, the leucine-rich repeat-containing G-protein
coupled receptors (LGR4, 5, 6) and their ligands, the R-Spondins
(Rspos) [16]. LGR-Rspo complexes at the cell membrane decrease the
endocytic turnover of Frizzled-LRP5/6 by neutralising the ubiquitin
ligases RNF43 and ZNRF3 [17]. Oncogenic Wnt/β-catenin
signalling is best exemplified in colorectal cancers where activating
mutations in β-catenin or loss of APC (Adenomatosis Polyposis Coli)
function (a key destruction complex protein) results in high
cytoplasmic and/or nuclear β-catenin [18], constitutive β-catenin-TCF/
Lef activity and expression of canonical Wnt target genes, such as
MYC and CCND1 [15]. In other cancers such as medulloblastoma,
however, Wnt pathway activation is associated with a more
favourable clinical subtype distinct from the more aggressive c-MYC
driven subtype [19].
In neuroblastoma, mutations in Wnt pathway components have
only been reported very recently [20], and identified mutations
predicted to have high functional impact in a Wnt geneset defined by
the KEGG database, and included NFATC1, FBXW11, TP53,
AXIN2, LRP5, CCND1, FZD9, DVL2, FOSL1, WNT7B, VANGL1,
LEF1, and PPP3CB genes. Interestingly, the latter three gene
mutations introduce premature termination, suggestive of a tumour
suppressive role of Wnt signalling in neuroblastoma. Other studies in
neuroblastoma have suggested that oncogenic deregulation of Wnt
signalling occurs, primarily based on over-expression of canonical
Wnt pathway target genes identified in other tissues and cancers.
Examples include high FZD1 expression associated with chemoresis-
tance [21], FZD6 marking highly tumorigenic stem-like cells in
mouse and human neuroblastoma [22], and FZD2-dependent
proliferation of neuroblastoma lines [23]. Furthermore, deregulatedWnt has been suggested to drive the over-expression ofMYC in non-
MYCN amplified (non-MNA) high-risk neuroblastomas [24].
Conversely, however, another study utilising chemical agonists and
inhibitors of the Wnt pathway has suggested that Wnt signalling
hyperactivation directs neuroblastoma cells to undergo apoptosis, and
inhibition of Wnt signalling blocks proliferation and promotes
neuroblastoma differentiation [25].
Our previous work reported high expression of the Wnt modulator
LGR5 in a subset of neuroblastoma cell-lines as well as poorly
differentiated primary neuroblastomas [26]. Using a TCF/Lef reporter
assay (TOPFLASH), we showed that three LGR5-expressing neuro-
blastoma cell-lines with different oncogenic drivers, SK-N-BE(2)-C
(MNA), SH-SY5Y (ALK mutant) and SK-N-AS (NRAS mutant)
displayed highly inducible β-catenin-TCF/Lef-regulated transcription
when treated with recombinantWnt3a and R-Spondin 2 (Rspo2), with
a strong requirement for LGR5/Rspo2 apparent for maximal induction,
as Wnt3a/Rspo2 induction of TOPFLASH was at least 5-fold greater
than with Wnt3a alone. Although these neuroblastoma cell lines
underwent apoptosis after short-interfering RNA (siRNA)-mediated
LGR5 knockdown, depletion of β-catenin did not affect cell survival.
This suggested that apoptosis after LGR5 depletion occurred
independently of Wnt/β-catenin signalling, and further analyses
demonstrated a novel pro-survival regulatory influence of LGR5 on
MEK/ERK signalling, independent of Wnt/β-catenin signalling [26].
This dual regulatory capacity of LGRs was subsequently also
demonstrated in skin carcinogenesis [27].
Although our previous study showed that several established target
genes of canonical Wnt signalling were induced in the neuroblastoma
cell lines treated with Wnt3a/Rspo2, including AXIN2 and LEF1, we
found that SOX2, MYC and MYCN, which were shown to be Wnt
pathway target genes studies in other tissue systems (http://web.
stanford.edu/group/nusselab/cgi-bin/wnt/), did not exhibit strong
induction. In fact, MYC and MYCN protein levels, as well as the
activated kinases Akt and ERK, were reduced after Wnt3a/Rspo2
treatment [26]. This, together with the seemingly discrepant
literature on Wnt-mediated effects on neuroblastoma cells, prompted
us to identify bona fide Wnt target genes in neuroblastoma using
RNA sequencing of SK-N-BE(2)-C cells treated with Wnt3a/Rspo2,
and thereafter correlate the neuroblastoma Wnt signature with
clinical parameters. These analyses, together with our evaluation of
Wnt3a/Rspo2 effects on neuroblastoma cell biology, reveal that Wnt
regulates recently discovered drivers of differentiation such as EPAS1
[28] and BMP4 [29] in cell lines that undergo differentiation. Our
study also demonstrates further complex interactions between Wnt
signalling and other regulatory pathways likely to be involved in
neuroblastoma development.Materials and Methods
Neuroblastoma Cell Lines and Culture Conditions
Neuroblastoma cell lines were from Carmel McConville (University
of Birmingham). The cell lines were grown in DMEM/Nutrient
Mixture F-12 Ham (Sigma) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Life Technologies), 200 mM L-Glutamine (Sigma), 100
units/ml penicillin, 0.1 mg/mL streptomycin (Sigma) and 1% (v/v)
non-essential amino acids (Life Technologies). Prior to stimulation with
growth factors, cells were grown in the same medium under low serum
conditions, containing 1% (v/v) FBS for 24 hours.
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RNAs. Briefly, 3 x 105 cells were seeded in 6-well plates after reverse
transfection with 50 nM siRNA and RNAiMAX (Invitrogen), both
diluted in OptiMEM media (Invitrogen). Sequences for siRNAs are
shown in Supplementary Table 1.
Live Cell Imaging and Migration Assays
To monitor proliferation in real time, neuroblastoma cells were
seeded in a 96-well plate, in quadruplicates, in media containing 1%
(v/v) FBS (5000 cells/well). After incubation for 24 hours, cells were
treated with recombinant Wnt3a and/or R-Spondin2 (R&D Systems,
100 ng/mL each) using low serum conditions and transferred to the
IncuCyte ZOOM live cell imaging system (Essen BioScience).
Epidermal growth factor (Sigma) was used at 10 ng/mL. Images were
taken in four different fields in each well, every two hours and phase
confluence was calculated as a surrogate for growth at each time
point. To measure cell death, DRAQ7 (BD Biosciences), a dye that is
taken up by dead cells only and fluoresces at 678 nm, was added at
1.5 μM concentration and fluorescence was measured in the red
channel. To measure migration, cells were seeded at near confluent
levels (50000 cells/well) in ImageLock 96-well plates (Essen BioScience),
in quadruplicates, in media containing 1 % FBS (v/v). Cells were
stimulated with Wnt3a and/or R-spondin2 24 hours later, and,
following another 24 hours, scratched by using the WoundMaker tool
(Essen BioScience) according to manufacturer’s instructions. Migration
was monitored at every 2 hours automatically, and wound width and
relative wound density were calculated for every time point.
RNA Sequencing and Bioinformatic Analyses
Serum-starved SK-N-BE(2)-C cells were stimulated with 100 ng/mL
Wnt3a and R-spondin2 in duplicates, for 6 hours and were
subsequently harvested. Previously, a systematic analysis of Wnt-
induced transcriptomic changes showed that 6 hours was the earliest
point whenWnt phenotypic response genes were robustly affected [30].
Control cells were treated with the vehicle, 0.2% (w/v) BSA in PBS.
RNAwas extracted by usingmiRNeasyMini Kit (Qiagen), according to
manufacturer’s instructions. RNA concentration and quality was
checked by using Nanodrop spectrophotometer and Bioanalyzer
(Agilent). All RNA integrity values (RIN) were above 9. cDNA
libraries were prepared from 1 ug RNA as template, using the TruSeq
Stranded Total RNA Library Prep Kit (Illumina) according to
manufacturer’s instructions. The libraries were sequenced by using
the paired-end option with 100 bp reads on Illumina HiSeq 2000 and
min. 50million reads were obtained per sample. Formatting and quality
control (FASTQC v0.11.5, Babraham Institute) were performed by
using theGalaxy platform [31] installed at theUniversity of Bristol. The
paired end reads were then aligned to the human genome (hg38) by
using TopHat2 (v2.0.14) [32]. The resulting alignment files (BAM)
files were uploaded to SeqMonk v1.38 (https://www.bioinformatics.
babraham.ac.uk/projects/seqmonk/). Gene expression was quantified
by using the Seqmonk RNA-seq analysis pipeline, with the option of
choosing reads along mRNA features as a basis of quantification.
Differentially expressed genes (DEG) were identified as showing
significant changes by either DESEQ2 [33] or Intensity Difference
Testing (Seqmonk) algorithms (pb0.005) between Wnt3A/Rspo2
treated and control sample sets, and having a fold difference of
minimum 1.3. RNA sequencing data is available from the European
Nucleotide Archive (ENA) under the study accession number
PRJEB21488.We performed Gene Signature Enrichment Analysis (GSEA) [34]
on a preranked list of relative gene expression values (log2-
transformed average Wnt3A/Rspo2 treated per control) with the
classic weighting option, as recommended for RNA-seq data (Broad
Institute). Analysis of gene set interconnectivity and enrichment of
Gene Ontology (GO) categories was performed by using tools of the
STRING database [35] (http://www.string-db.org). Gene expression
and gene set correlations in published RNA-seq and microarray data
sets were analysed by using the R2 Genomics Analysis and
Visualization Platform (http://r2.amc.nl). Clustering of Wnt target
gene expression in the SEQC neuroblastoma RNA-seq data set was
performed by using k-means clustering in R2. The option of k=4
provided the best separation of clusters. Wnt metagene groups were
defined based on the the similarity of co-expression of the Wnt target
genes calculated during clustering. Wnt metagenes were defined as
having an average expression of the members of the metagene group.
Kaplan Meier survival analysis, indicating the prognostic value of the
expression of genes or metagenes was performed by using the Kaplan
scan tool in R2. Briefly, Kaplan scan selected the expression threshold
providing the best statistical significance of the separation of
outcomes associated with high and low expression of a gene or
metagene, using the log-rank test.
RNA Extraction and qRT-PCR
RNA was extracted using the miRNeasy Mini Kit (Qiagen)
according to manufacturer’s instruction and subsequently transcribed
into cDNA by using the Thermoscript kit (Invitrogen). Quantitative
PCR was performed on an Mx4000P machine (Stratagene) using
QuantiNova kit (Qiagen) and analysed according to the comparative
Ct method, normalizing values to the housekeeping gene TBP.
Primer sequences are shown in Supplementary Table 1.
Immunoblotting and Immunohistochemistry
Immunoblotting was essentially as described previously [36]. The
antibodies used were the following: E2F1 andMYCN (Santa Cruz, SC-
251 and SC-53993 respectively, 1:1000), BMP4 (4680s), CCND1
(2978s), EPAS1 (7096s), NGFR/p75NTR (8238S) phospho-RB
(8516s), all Cell Signalling, 1:1000) and beta-actin-peroxidase
(A3854, Sigma, 1:40000). Peroxidase conjugated secondary antibodies
(Sigma) were diluted 1:5000 and the blots were developed using
LumiGLO Peroxidase Chemiluminescent substrate (KPL).
Immunohistochemistry was conducted essentially as described
previously [36]. Neuroblastomas were collected at The Children’s
Hospital at Westmead Histopathology Department (Sydney, Australia).
All human tissues were acquired with appropriate local research ethics
committee approval. The β-catenin antibody (Cell Marque, 760-4242)
was used after pH8.5 heat retrieval. Staining excluded post-treatment
samples which displayed extensive necrotic areas.
Results
Wnt3a/Rspo2 Drives a Unique Transcriptional Program in
Neuroblastoma, Affecting Multiple Pathways.
We characterised Wnt3a/Rspo2-induced early transcriptomic
changes in the MNA neuroblastoma cell line, SK-N-BE(2)-C.
Using a bioinformatic cut-off of p=b0.005 along with a minimum
fold change of 1.3, RNA-sequencing identified 90 genes showing
significant changes in expression (Figure 1A). Eighty-five of the
differentially expressed genes (DEGs) were upregulated, with 5 genes
Figure 1. Identification of novel Wnt target genes in neuroblastoma. (A) Heatmap depicting 90 differentially expressed genes (DEGs) in
Wnt3A/Rspo2 treated SK-N-BE(2)-C cells (WR) at 6 hours vs. control (C), as determined by RNA-seq (n=2). (B) Venn diagram comparing
the 90 Wnt3A/Rspo2-regulated genes in SK-N-BE(2)-C to Wnt target genes in colorectal cancer (LS174T), glioma (U87) and embryonic
kidney cells (HEK293), previously determined by using ChIP-seq. The table lists thirty-seven Wnt target genes uniquely identified in
neuroblastoma cells. Wnt feedback/negative regulator genes are shown in red. (C) Gene Set Enrichment Analysis (GSEA) of gene
expression changes in Wnt3A/Rspo2-induced SK-N-BE(2)-C cells at 6 hours, using the Reactome and Hallmark databases. Respective
corrected p values (p FWER) and normalized enrichment scores (NES) are shown. WR, treated; C, control.
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RGS16, HS6ST1, NME2 and TMEM108-AS1).
In order to assess whether our 90DEGs had been previously identified
as direct targets of β-catenin/TCF-/Lef in other cell types, we compared
our gene list with published target genes of canonical Wnt signalling,
based on using ChIPseq in U87 glioma cells [37], HEK293, and the
colorectal cancer cell line LS174T [38]. Fifty-three out of the 90 DEGs
were identified as having β-catenin and/or TCF7L2/TCF4 bound totheir promoters in one or more of these three data sets (Figure 1B and
Supplementary Table 2). To our knowledge, however, Wnt-dependent
increase of transcription has not been demonstrated for many of these 53
genes, including LIX1, S1PR1, FAT4, HTR1E, ETV6, TSHZ1 and
NEDD9. As often seen with induction of Wnt signalling, several genes
encoding negative regulators of the pathway are observed amongst the
DEGs, including AXIN2, NKD1, TNFRSF19, ZNRF3, KREMEN,
AMER1 and VLDLR. Of the 37 genes not encompassed by the CHiP-seq
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shown to be induced byWnt signalling, and all genes exhibited TCF7L2
binding according to ENCODE/SYDHChIPseq data (data not shown).
Thus our dataset identifies novel Wnt target genes likely to have roles in
cell-fate decisions in neuronal development and neuroblastoma.
We found genes encoding neuronal proteins were induced by
Wnt3a/Rspo2, including several neurotransmitter receptors (HTR1E,
HTR2B, NPY2R, ADRA2A and OPRM1), neurofilament protein M
(NEFM), and transcription factors involved in differentiation of the
neural crest, including MSX1 and MSX2 [42]. EPAS1/HIF-2α,
which was very recently associated with differentiation of neuroblas-
toma [28] was also upregulated after treatment. ASCL1, which is one
of the few down-regulated genes amongst the DEGs, is also involved
in neuronal differentiation [43], with mRNA downregulation also
observed with retinoic acid induced differentiation of neuroblastoma
cells [44]. Numerous other transcription factors were also induced
such as ETS1, ETV6, LHX9, TSHZ1, TSHZ2, ZEB2 and ZNF503,
indicating complex transcriptional networks triggered by Wnt
signalling. Functional annotations for the 90 DEGs are shown in
Supplementary Table 2. Analysis of Wnt3a/Rspo2-induced global
gene expression changes using Geneset Enrichment Analysis (GSEA)
further confirmed induction of neural differentiation pathways (TrkA,
nerve growth factor (NGF),NGFR/p75NTR, axon guidance) (Figure 1C).
In addition GSEA highlighted influences on numerous signalling
pathways, including Wnt, Notch, and Rho GTPase (Figure 1C).
Further pathways and processes affected included Hedgehog,
mTORC1, and EGFR signalling, as well as glycolysis, oxidative
phosphorylation and mRNA splicing (Supplementary Table 3).
Epithelial-mesenchymal transition (EMT), which is integral to neural
crest differentiation, was also apparent, and, consistent with our previous
observation of increased Ki67 following Wnt3a/Rspo2 treatment,
effects on the cell cycle and mitosis were evident (Figure 1C) [26].
Using qRT-PCR, we validated 27 of the DEGs in SK-N-BE(2)-C
cells and in two other Wnt3a/Rspo2 responsive neuroblastoma cell
lines with different driver mutations, SK-N-AS (NRAS mutant) and
SH-SY5Y cells (ALK mutant) following 6 hours and 24 hours of
Wnt3a/Rspo2 treatment. While many DEGs were also upregulated
(greater than 1.3-fold at 6 hours) in the other two cell lines, the Wnt
response in SK-N-AS was more dissimilar and shared 63% of target
genes with SK-N-BE(2)-C, compared with 89% for SH-SY5Y
(Supplementary Figure 1). Generally, we observed gene induction at
6 and 24 hours, indicating a sustained transcriptional response in SK-
N-BE(2)-C and SH-SY5Y. EPAS1, FAT4, KREMEN1 were not
induced in SK-N-AS cells at either time-point (Supplementary Figure
1A). R-spondin 2 alone did not significantly affect the expression of
these genes (Supplementary Figure 1B). Database analysis indicated
that the Frizzled receptor status of SK-N-AS cells may differ from the
other lines (Supplementary Figure 1C), but more extensive analyses
beyond the scope of this study are necessary in order to support this.
Taken together, analyses of our novel neuroblastoma Wnt target
genes suggests that Wnt signalling may have profound effects on
differentiation as well as proliferation via a complex orchestration of
downstream transcription factors and signalling pathways.
Wnt Signalling Affects Growth and Differentiation in a
Context-Dependent Manner
As our transcriptomic data showed effects on differentiation
associated genes such as ASCL1, BMP4, NEFM, and EPAS1, and
GSEA also indicated stimulation of neuronal differentiation pathwaygenesets, we next assessed the phenotypic effects of Wnt signalling on
SK-N-BE(2)-C, SH-SY5Y and SK-N-AS cell-lines. As shown in
Figure 2A, treatment of SK-N-BE(2)-C cells with Wnt3a/Rspo2
induced morphological changes indicative of differentiation, includ-
ing a more mesenchymal appearance and increased neurite-like
projections. Using real-time, live-cell imaging, we quantified changes
in cell confluence, and observed no significant proliferative effects
with Wnt3a or Wnt3a/Rspo2, in contrast to the positive control EGF
(Figure 2B, left panel). However, a significant increase (p=b0.01) of
neurite length and neurite branch points was apparent in Wnt3a/
Rspo2 treatments, beginning around 24 – 30 hours. Wnt3a alone also
induced characteristics of neural differentiation in SK-N-BE(2)-C
cells, but at later time points (33 – 39 hours) and at a lesser level (p=
b0.05) (Figure 2B, middle and right panels). This is consistent with the
observed changes corresponding toWnt signalling amplitude, which we
showed were increased with Wnt3a/Rspo2 co-treatment [26].
Given the morphological changes observed, and our GSEA
analyses, we next evaluated markers of EMT and neural differenti-
ation in Wnt3a/Rspo2 treated cells. Induction of fibronectin (FN1),
as well as the EMT transcription factors SNAI1, SNAI2, TWIST1
and TWIST2 was apparent in SK-N-BE(2)-C cells 24 hours after
Wnt3A/Rspo2 treatment (Figure 3C). Analysis of genes that are
increased with retinoic acid induced differentiation of neuroblastoma
cells (NGRF, NF68, NTRK1, SYP, MAP2, NEFM, DKK2) [45–47]
showed that all were elevated after 72 hours Wnt3a/Rspo2 treatment.
Downregulation of ASCL1 was also observed (Figure 3D). The
parallels betweenWnt and retinoic acid effects were further supported
by comparing our DEGs with an array analysis of SH-SY5Y cells,
which shows that many Wnt genes are similarly altered by retinoic
acid (Supplementary Figure 2). Differentiation was also verified at the
protein level for NGFR/p75NTR, which was markedly increased
after Wnt3a/Rspo2 treatment, with a moderate increase also observed
with Wnt3a alone (Figure 2E). As we observed EMT-like changes,
and differentiation induced by all-trans-retinoic acid (ATRA) has also
been shown to increase cell migration [48], we evaluated the effects of
Wnt induction in a wound-healing/scratch assay. Consistent with our
mRNA marker data, Wnt3a/Rspo2 treatment led to increased
migration (Figure 3F) and a significantly increased wound cell density
from 22 hours post-treatment (p=b0.01, Figure 3G), with more
moderate effects also observed with Wnt3a treatment alone at later
time points. Together, these results are consistent with Wnt3a/Rspo2
leading to differentiation of SK-N-BE(2)-C cells akin to that induced
by retinoic acid.
We performed similar analyses with SH-SY5Y cells and observed
comparable morphological changes to those seen with SK-N-BE(2)-C
cells (Figure 3A). However, real-time quantification of cell confluence
revealed that, in contrast to SK-N-BE(2)-C cells, the growth of SH-
SY5Y cells was inhibited by Wnt3a alone from 26 hours onwards (p=
b0.05). Dual treatment with Wnt3a/Rspo2 also led to growth
inhibition beginning at about 26 hours and becoming significant at
about 56 hours (p=b0.01). Although more delayed, the extent of
growth inhibition was greater with the dual treatment (Figure 3B, left
panel). Both Wnt3a and Wnt3a/Rspo2 treatments led to an increase
in neurite length, but the Wnt3a effect attenuated after approximately
16 hours, whereas the Wnt3a/Rspo2 treated cells continued to show
increasing neurite length and also increasing branch points from 16
hours onwards. Of the EMT markers, SNAI2 and both TWIST genes
were induced after Wnt3a/Rspo2 treatment (Figure 3C), and
induction of neural differentiation genes was also clearly apparent
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induction were observed at the protein level between Wnt3a and
Wnt3a/Rspo2 treatments (Figure 3E), and both treatments led to
increased cell migration (Figure 3F, G). Together these data support
the differentiation inducing influence of Wnt signalling on SH-SY5Y
cells, similar to that observed in SK-N-BE(2)-C cells.
We also evaluated the effects of Wnt3a/Rspo2 treatment on a third
LGR5-positive neuroblastoma cell line, SK-N-AS. In marked contrast
to SK-N-BE(2)-C and SH-SY5Y cells, we observed no morphological
changes after treatments, as well as a robust increase in proliferation
(Supplementary Figure 3A, B). Consistent with the lack of visible
phenotypic changes, most differentiation markers did not increase, as
assessed by qRT-PCR, and some of them decreased. Further, in
contrast to SK-N-BE(2)-C and SH-SY5Y cells, NGFR/p75NTR
protein negatively correlated with Wnt signalling amplitude, reducing
with Wnt3a alone and decreasing further still with Wnt3a/Rspo2
treatment (Supplementary Figure 3C, D). In contrast to a previous
report [25], we did not observe Wnt signalling associated cell death
(Supplementary Figure 2E). We further explored whether the
proliferative response of SK-N-AS cells may be characteristic of
their more mesenchymal state, as defined recently [4], by assessing
proliferation in another mesenchymal line, GI-MEN. However,
Wnt3a/Rspo2 treatment did not trigger proliferation in this line
(Supplementary Figure 3F).
To further evaluate the growth and differentiation variance of these
cell lines at the protein level, we examined whether induction of two
recently characterised inducers of differentiation, BMP4 [29] and
EPAS1 [28], corresponded with the propensity of cells to
differentiate. As shown in Figure 4A, although BMP4 and EPAS1
were induced by Wnt signalling in the differentiating cell-lines (SK-
N-BE(2)-C and SH-SY5Y), their levels in SK-N-AS cells were
unchanged. In contrast, assessment of cell-cycle/proliferative markers
demonstrated an increase in CCND1 and E2F1 only in SK-N-AS
cells. Consistent with our real-time differentiation and proliferation
assays, SH-SY5Y cells showed decreased CCND1, E2F1 and
phosphorylated RB proteins (Figure 4B).
Together our phenotypic analyses show that Wnt signalling can
induce a more neuronal phenotype in SK-N-BE(2)-C and SH-SY5Y
cells, with no increase in cell proliferation. In SK-N-AS cells,
however, quite the opposite was apparent, with Wnt signalling
inducing cell proliferation without differentiation.
Primary Neuroblastoma Gene Expression Datamining Reveals
that Wnt Target Genes are Associated with Distinct
Prognostic Groups
Having shown that Wnt induction can prompt differentiation and
growth suppression, or in the case of SK-N-AS cells, proliferation, we
next evaluated the clinical correlations of our 90 Wnt pathway DEGs
in publicly available primary neuroblastoma expression data. Firstly,Figure 2. Differentiation and migration of SK-N-BE(2)-C cells after Wnt
and Wnt3A/Rspo2 treated SK-N-BE(2)-C cells at 48 hours. (B) Phase c
live-cell imaging. EGF treatment was used as a positive control for pro
by using IncuCyte NeuroTrack software. Significance was evaluated a
qRT-PCR of transcription factors driving epithelial-to-mesenchymal tr
PCR of neuroblastoma differentiation markers in Wnt3A/Rspo2 induc
Wnt3A/Rspo2 and control cells at 72 hours. β-actin was used as loa
assay, measuring migration after Wnt3A and Wnt3A/Rspo2 treatmen
migrating cells are highlighted in blue. (G) Relative wound density p
proliferation by Incucyte software (n=4). Significance was tested atusing k-means clustering, we assessed whether patterns of expression
of the DEGs existed in a large neuroblastoma cohort (SEQC, n=498,
[49]). Strikingly, this analysis revealed that the cohort could be
partitioned into 4 clear patient clusters, each with a distinctive
expression pattern of our DEGs; in turn, the DEGs could also be
grouped into 4 sets, from which we could derive 4 model genes, or
Wntmetagenes (WMG-1, -2, -3 and -4) for further analyses (Figure 5A).
Such metagenes enable using a single value to represent the combined
expression values of multiple co-expressed genes.
Of the 4 patient clusters, cluster 3 (blue) and 4 (orange) had high
representation of high-risk neuroblastoma (85%, 137/160), as
defined by the SEQC dataset, with cluster 3 being composed of
mainly MNA tumours (81%, 84/104). This demonstrates the
efficacy and veracity of the k-means clustering, which is further
supported by the Kaplan-Meier analysis of our k-means derived
clusters, where poor overall survival could be ranked as cluster
3Ncluster 4Ncluster2Ncluster 1 (Figure 5B). The expected association
of cluster 3 with MYCN over-expression was apparent and MYC
expression was significantly higher in cluster 4, the second cohort
associated with very poor prognosis (Figure 5C). We also tested
correlations with other neuroblastoma oncogenes, TERT and
LIN28B. These were also higher in clusters 3 and 4 designated by
our analyses (Supplementary Figure 4).
With regard to metagene expression patterns between the patient
clusters, contrasting patterns of high or low expression were clearly
apparent. In the predominantly MNA cluster 3, WMG-2 genes were
expressed at low levels compared to other clusters; conversely WMG-
3 genes were highly expressed in cluster 3 (Figure 5A). Kaplan-Meier
analysis of WMG-2 in four neuroblastoma datasets demonstrated that
low WMG-2 expression is an indicator of poor prognosis (Figure 5D,
left), Supplementary Figure 5A-C). Notably, although we identified
WMG-2 in the predominantly MNA cluster 3, Kaplan-Meier
analysis of low-risk tumours in the SEQC dataset (n=322) with
WMG-2 demonstrated a highly significant association of low WMG-
2 with poor survival (p=8.2 x 10-9) (Figure 5D, right). Further
assessment of low-risk, non-MNA amplified neuroblastomas across
several databases confirmed that a WMG-2(low) signature may help
in identification of patients with poor prognosis, despite being
classified as lower risk (Supplementary Figure 5A-C).
Conversely, high expression of WMG-3 was associated with poor
prognosis across the four datasets, and a WMG-3(high) signature
could also identify low risk patients with poor prognosis, albeit with
less specificity (Figure 5E, Supplementary Figure 5D-F). The
prognostic value of WMG-1 was not as strong as that of WMG-2
or WMG-3, but high expression was associated with better prognosis,
after exclusion of MNA tumours. Although this trend was apparent in
other datasets, it did not always reach the high levels of significance
seen with WMG-2 and WMG-3 (Supplementary Figure 5G). The
WMG-4 metagene did not have clear prognostic value, as would be3A/Rspo2 induction. (A) Phase contrast microscopy of control, Wnt
onfluence was monitored as a surrogate for growth using IncuCyte
liferation. Neurite lengths and neurite branch points were quantified
t every time point by using T tests at pb0.01 (***) and pb0.05 (*). (C)
ansition (EMT) in Wnt3A/Rspo2 induced cells at 24 hours. (D) qRT-
ed cells at 72 hours. (E) Western blot of NGFR/p75NTR in Wnt3A,
ding control. (F) Representative fields of a 96-well scratch wound
t vs control (n=4). The original wound is shown in green and the
lot, showing cell confluence within the wound area corrected for
every time point by using T tests at pb0.01 (***) and pb0.05 (*).
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Figure 4. Induction of pro-differentiation and proliferation proteins
by Wnt3a/Rspo2 treatment. (A) Immunoblotting of BMP4 and
EPAS1 after 48 hours of treatment shows increases in SK-N-BE(2)-
C and SH-SY5Y cell-lines, but not in SK-N-AS. (B) Immunoblotting of
CCND1, E2F1 and phospho-RB shows increases in SK-N-AS, but
not in SK-N-BE(2)-C and SH-SY5Y cell-lines.
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constituent genes (Figure 5A, Supplementary Figure 5H).
As WMG-2 and WMG-3 show distinctive and opposite expression
patterns in the predominantly MNA cluster 3, we assessed the
correlations of these metagenes with a MYC target gene dataset. In the
SEQC data set, a strong inverse correlation (R=-0.76, p=7.86 x 10-95)
was observed between the Hallmark MYC target genes and WMG-2
(Figure 5F). WMG-3, as expected, had a strong positive correlation
with MYC target genes (R=0.61, p=2.29 x 10-52), although the two
gene sets did not have any genes in common. Remarkably,WMG-2 also
had a striking positive correlation (R=0.85, p=9.14 x 10-134) with a
published gene set representing genes downregulated in poor prognosis
non-MNA neuroblastoma (Asgharzadeh_NB_poor_survival_DOWN)
[50], despite only sharing one gene (PGM2L1) (Figure 5G). An
inverse correlation of the Asgharzadeh gene set with WMG-3 was
also apparent, but less significant, as expected given that this geneset
is limited to non-MNA tumours. Together this reinforces that high
expression of theWMG-2metagene is an indicator of good prognosis
regardless of MYCN statusFigure 3. Differentiation and migration of SH-SY5Y cells after Wnt3A/R
Wnt3A/Rspo2 treated SH-SY5Y cells at 48 hours. (B) Phase confluenc
positive control. Neurite lengths and neurite branch points were calcu
significance was evaluated by using T tests at pb0.01 (***) and pb0.
Rspo2 induced cells at 24 hours. (D) qRT-PCR of neuroblastoma diff
Western blot of NGFR/p75NTR in Wnt3A, Wnt3A/Rspo2 and con
Representative fields of a 96-well scratch wound assay, measuring m
The original wound is shown in green and the migrating cells are h
confluence within the wound area corrected for proliferation by Incuc
using T tests at pb0.01 (***) and pb0.05 (*).Immunohistochemical Analysis of β-catenin in Primary
Neuroblastomas
Our transcriptomic and functional data, together with recent
mutation analysis [20], indicate that a canonical Wnt programme
may be more active in lower stage neuroblastoma and decreased/
suppressed in higher stage neuroblastomas. We therefore examined β-
catenin protein expression at the cellular level in neuroblastoma tissue
sections. As shown in Figure 6A, poorly differentiated non-MNA
neuroblastomas showed very weak or negative staining, and a MNA
poorly differentiated tumour exhibited a low level of focal
membranous positivity (Figure 6B). In contrast to these stroma
poor tumours, stroma rich neoplasms, ganglioneuroblastomas and
ganglioneuromas, showed membranous β-catenin staining of differ-
entiating neuroblasts (Figure 6C) and maturing and mature ganglion
cells (Figure 6C and D), which were embedded in Schwannian
stroma. Interestingly, Schwannian stroma displayed intense and
extensive cytoplasmic and membranous β-catenin positivity in the
Schwann cells, as well as some nuclear staining (Figure 6C and D). In
these, stroma rich tumours, Schwann cell condensation and increased
β-catenin levels were detected around ganglion cells (Figure 6D).
Taken together, these results are supportive of our transcriptomic and
functional data suggesting that Wnt signalling may prompt
differentiation signals for neuroblasts, and further suggest that
Schwann cells, which have been shown to promote neuroblast
differentiation [51,52], may be the source of Wnt3a/Rspo2-induced
signalling ligands.
The Influence of MYCN on Wnt Signalling and Other
Potential Cross-Talk
Our transcriptomic clustering (Figure 5A) revealed that certain
groups of genes had a very distinctive distribution pattern between the
four patient clusters. In particular genes comprising WMG-2 were
expressed at markedly lower levels in MNA tumours. We therefore
assessed whether MYCN might directly control these genes.
Consistent with MYCN repressing WMG-2 genes, depletion of
MYCN by short-interfering RNA (siRNA) in SK-N-BE(2)-C cells
led to a 2 – 8-fold induction of nine out of eleven WMG-2 genes
tested, including DCLK3, EPAS1, FAT4 and NRP1 (Figure 7A, B).
The effect of MYCN knockdown on WMG-1 and 3 genes was more
variable, but ETV6, BMP4 and WNT11 were increased, and NKD1,
LIX1 and NME2 transcripts were reduced as would be predicted by
our clustering data.
We next analysed whether WMG-1, 2 and 3 are not simply sets of
co-regulated genes, but whether they are also functionally linked.
Interconnectivity analysis in the STRING protein-protein interaction
database suggested that this was indeed the case, demonstrated by
their significantly higher connections than expected by chance (Table 1).
In contrast, genes in WMG-4 did not appeared to be functionally
connected. The functional relevance of the Wnt metagene groups inspo2 induction. (A) Phase contrast microscopy of control, Wnt and
e was monitored as a surrogate for growth and EGF was used as a
lated by using IncuCyte NeuroTrack software at every timepoint and
05 (*). (C) qRT-PCR of transcription factors driving EMT in Wnt3A/
erentiation markers in Wnt3A/Rspo2 induced cells at 72 hours. (E)
trol cells at 72 hours. β-actin was used as loading control. (F)
igration after Wnt3A and Wnt3A/Rspo2 treatment vs control (n=4).
ighlighted in blue. (G) Relative wound density plot, showing cell
yte software (n=4). Significance was tested at every time point by
Figure 5. Expression patterns of the 90 identifiedWnt target genes in primary neuroblastomas (A) K-means clustering in 498 neuroblastoma
tumours (SEQC data set). In the heatmap red indicates high, while green shows low expression. Annotation of patient samples are shown at
the top in the following order: risk (high: red, low: green), INSS stage (1: green, 2: dark green, 3: orange, 4: red and 4S: blue), MYCN
amplification (MNA: red, non-MNA:green), outcome (survival: yellow, died of disease: red) and progression (no progression: yellow, relapse:
red). The result of each iterative round of clustering with k=4 is indicated with rows of yellow, purple, blue and orange coloured squares.
Clustering highlighted 4 groups of co-expressed genes that were represented with metagenes (WMG-1 to 4, shown on the right). (B) Kaplan
Meier analysis (log rank test) of the four patient clusters exhibiting significantly different survival. (C) Expression ofMYCN andMYC in the 4
neuroblastoma clusters. Significance assessed by T tests. (D) Kaplan Meier survival curves associated with expression of WMG-2 in SEQC
data set. All patients and low-risk patients are shown separately. Bonferroni-corrected p values of log rank test are shown. (E) Kaplan Meier
analysis ofWMG-3 as in (D). (F) CorrelationofWMG-2 and 3withMYC target genes and (G) Asgharzadeh’s set of downregulatedgenes in non-
MNA metastatic neuroblastoma (curated gene sets, Broad Institute) in SEQC. Correlation coefficients (R) and p values are shown.
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Ontology/Biological Process (GO/BP) categories. WMG-1 was found to
be significantly enriched in 117 categories, broadly representing
mesenchyme development, cellular migration, angiogenesis and regula-
tion of proliferation. WMG-2 contained genes participating in
sympathetic neuron projection and guidance, processes involved in
neuronal differentiation, whereas WMG-3 and WMG-4 genes included
several negative regulators of signalling pathways (AMER1, ASCL1,Figure 6. Immunohistochemistry of β-catenin in primary neuroblasto
differentiated neuroblastoma, MNA (C) Ganglioneuroblastoma and
Homer-Wright rosettes; NB, neuroblasts; dNB, differentiating neurobAXIN2, DUSP4, ENC1, GRK5, NKD1, TNFRSF19, VLDLR, and
ZNRF3).
We have already shown that Wnt3a/Rspo2 treatments could lead
to decreases in other signalling pathways such as Akt and ERK
signalling [26]. To further characterize signalling cross-talk and its
possible biological significance, we searched for correlations between
the metagenes and KEGG and Hallmark genesets (Figure 7C) and the
Broad Institute curated gene sets (Figure 7D, E) within themas. (A) Poorly differentiated neuroblastoma, non-MNA. (B) poorly
maturing ganglioneuroma. (D) Ganglioneuroma. Labelled are HR,
lasts; G, Ganglion cells; S, Schwannian Stroma.
Figure 7. MYCN regulation of Wnt target genes. (A) Western blot of MYCN and β-actin, as loading control, 48 hours after MYCN
knockdown in SK-N-BE(2)-C cells. (B) Changes in expression of Wnt target genes belonging to WMG-1, 2 and 3 following MYCN
knockdown at 48 hours. (C) Correlation of Wnt metagenes with expression of curated gene sets at pb10-10 (***), pb10-5 (**) or pb0.01 (*).
(D) Correlations with Broad Institute curated sets for WMG-1 (E) Correlations with Broad Institute curated sets for WMG-2.
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regulators of cell migration, EMT, Rho-GTPase activation and Notch
signalling (Figure 7C), as well as Hippo/Yap signalling (Figure 7D).
WMG-2 shared many of these correlations, but to a lesser extent. The
highest correlations for WMG-2 was with gene sets driving neuronal
differentiation, axonogenesis and maintaining cell polarity. Members of
the Hedgehog pathway, an important driver of neural crest and
neuroblastoma differentiation [53,54], were also strongly associated with
WMG-2 (Figure 7C). Broad genesets also revealed strong correlations
of WMG-2 with alternative branches of the Wnt pathway such as the
Wnt/Ca2+/cyclic GMP pathway and DAG/IP3 signalling (Figure 7E).WMG-3 showed strongest positive correlations for ribosome biogenesis,
DNA damage check points, unfolded protein response and E2F target
genes, which are all linked to high MYCN activity, and WMG-3 was
generally anti-correlated withWMG-1 andWMG-2 gene sets.WMG-4
was associated with upregulation of metabolic pathways, including
glycolysis, cholesterol homeostasis, glutamate pathway as well as
mTORC1 signalling.
Together, these analyses suggest that expression of the Wnt
metagene subsets is contingent on coregulatory axes. The most
notable of these is MYCN suppression of WMG-2 genes, which
likely represent genes critical for differentiation.
Table 1. STRING and Gene Ontology analysis of Wnt metagenes
Pathway ID Pathway description Count FDR
WMG-1 STRING connectivity: protein-protein interactions: n=7, p=5.31e-04
MSX2, TRIB1, WNT11, CHST2, ADAMTS14, PCDH18, EDNRA, MSX1, RGS16, RASSF3, ETV6, PALMD, NEDD9, ETS1, S1PR1, TBX18, ARHGAP24, ANGPT1, BMP4, HTR2B
GO:0060485 mesenchyme development 6 2.82E-05
GO:0048762 mesenchymal cell differentiation 5 1.13E-04
GO:0001568 blood vessel development 7 1.41E-04
GO:0001525 angiogenesis 6 2.52E-04
GO:0048585 negative regulation of response to stimulus 9 6.12E-04
GO:0042127 regulation of cell proliferation 9 1.40E-03
GO:0030513 positive regulation of BMP signaling pathway 3 1.50E-03
GO:0010464 regulation of mesenchymal cell proliferation 3 2.93E-03
GO:0030334 regulation of cell migration 6 4.84E-03
GO:0030335 positive regulation of cell migration 5 4.86E-03
GO:0008285 negative regulation of cell proliferation 6 5.60E-03
GO:0009968 negative regulation of signal transduction 7 7.12E-03
GO:0072089 stem cell proliferation 3 7.13E-03
GO:0070374 positive regulation of ERK1 and ERK2 cascade 3 2.98E-02
GO:0003198 epithelial to mesenchymal transition involved in endocardial cushion formation 2 9.51E-03
GO:0048870 cell motility 6 1.15E-02
WMG-2 STRING connectivity: protein-protein interactions: n=6, p=2.3e-03
ARHGEF28, ADRA2A, DKK4, FAT4, ZEB2, EPAS1, KREMEN1, TSHZ1, IRF2BP2, LHFPL2, LPAR1, NRP2, DCLK3, GOLGA7B, TSHZ2, ARHGAP22, ARHGEF3, EFNB2, NRP1, FNBP1L, DSEL,
PLCL1, ZBTB38, LPPR4, DLC1, PGM2L1, SCN9A, ATXN1
GO:0097490 sympathetic neuron projection extension 2 4.97E-02
GO:0097491 sympathetic neuron projection guidance 2 4.97E-02
GO:1900122 positive regulation of receptor binding 2 4.97E-02
WMG-3 STRING connectivity: protein-protein interactions: n=6, p=1.69e-02
SLC37A3, HIPK2, PPP2R5E, AMER1, ZNRF3, NKD1, GRK5, NPY2R, ASCL1, PRLHR, NME2, LIX1, LHX9, CACHD1, HDAC9, OPRM1, MARC1, ABCA12, DUSP4, CHODL, HTR1E, CDH10
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway 4 4.07E-02
GO:0010648 negative regulation of cell communication 8 4.07E-02
GO:0023057 negative regulation of signaling 8 4.07E-02
GO:0030815 negative regulation of cAMP metabolic process 3 4.07E-02
GO:0048585 negative regulation of response to stimulus 8 4.86E-02
WMG-4 STRING connectivity: protein-protein interactions: n=1, p=0.204
MMP16, SLC7A14, NEFM, HS6ST1, UBE2QL1, LINC00327, TNFRSF19, VLDLR, SEMA3A, RGS13, RGS2, GLRX, ENC1, C6orf132, ZNF503, AXIN2, FGFR2
GO:0038032 termination of G-protein coupled receptor signaling pathway 3 3.05E-02
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Wnt signalling is a key regulator of cell fate, capable of regulating
stemness, differentiation and proliferation. The proliferative activity is
often co-opted by cancer cells, acting via transcriptional transactiva-
tion of proto-oncogenes such as MYC and CCND1. In the case of
neuroblastoma, Wnt signalling has been proposed to be an oncogenic
driver of MYC over-expression in non-MNA tumours [24], although
our previous work did not detect significant increases of c-MYC or
MYCN protein after Wnt3a/Rspo2 treatment of neuroblastoma cell
lines [26]. In this study, we therefore defined the Wnt-driven
transcriptome in the MNA neuroblastoma cell line SK-N-BE(2)-C,
and also examined the phenotypes accompanying Wnt signalling
induced by recombinant Wnt3a and Rspo2 ligands. As well as
revealing new Wnt targets likely to be involved in sympathetic
nervous system development, and previously unrecognised signalling
crosstalk in neuroblastoma, we demonstrate that Wnt signalling can
prompt neuroblast differentiation, as well as proliferation of cell lines.
Evaluation of the expression of our Wnt gene set in primary tumours
reveals patterns of expression that are distinctive to different clinical
cohorts and prognosis, indicating that, broadly, a suppression of Wnt
signalling may be conducive to the development of high-risk
neuroblastoma. This is further supported by immunohistochemical
analysis of β-catenin staining, which is intense in ganglioneuromas
and ganglioneuroblastomas and relatively weak in poorly differenti-
ated neuroblastomas.
Of the 90 DEGs identified by our RNA-seq, 53 have previously
been implicated as Wnt target genes by β-catenin and TCF4 binding
to their promoters. We identified numerous transcription factorsdownstream of Wnt signalling, many of which have been shown to be
involved in neuronal differentiation and to act upstream of Wnt
signalling (ASCL1 [43,55], MSX1 and MSX2 [42], LHX9 [56], and
TSHZ1 [57]). This, together with the other transcription factors
(EPAS1, ETS1, ETV6, TBX18, TSHZ2, ZEB2, ZBTB38), as well as
epigenetic regulators/non-coding RNAs (HDAC9, KDM7A,
LINC00327, TMEM108-AS1, VLDLR-AS1) strongly supports Wnt
signalling as a master regulator of neuroblast cell fate. In addition,
crosstalk of Wnt signalling with several other signalling pathways can
be inferred from our DEGs. These include MAPK (DUSP4 [58],
HS6ST1 [59], TRIB1 [60]), Hippo-Yap/Taz (FAT4 [61], LIX1
[62], semaphorin (NRP1, NRP2, SEMA3A [63]) and small G-
protein/Rac/Rho signalling (ARHGAP22, ARHGAP24, ARH-
GEF28, ARHGEF3, DLC1, FNBP1L [64,65]).
Consistent with the absence of obvious proto-oncogene induction
within the DEGs, our examination of Wnt-induced phenotypes did
not show a proliferative effect in SK-N-BE(2)-C cells. Instead, we
observed clear neuritogenesis, concomitant with markers of EMT and
neuronal differentiation. Here EMT likely reflects a transitional
intermediate state with high plasticity that facilitates differentiation
[66]. A similar neuronal differentiation phenotype was observed in
SH-SY5Y cells lines, but in the case of SK-N-AS cells, we observed
Wnt-induced proliferation, as recently shown [23]. At the molecular
level, the different responses of these cell lines were accurately
reflected by changes in known drivers of differentiation (BMP4,
EPAS1, NGFR) and proliferation (CCND1, E2F1 and phospho-
RB). To our knowledge this is the first demonstration of Wnt ligands
inducing phenotypic differentiation of neuroblastoma cells, in
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very recent study suggested that the tankyrase inhibitor XAV939
reduces markers of differentiation in SH-SY5Y cells, although in
contrast to our work, that study observed no effects on morphology or
proliferation [67]. In another report using chemical Wnt agonists and
inhibitors, Wnt inhibition was found to block proliferation and
promote neuroblastoma differentiation, andWnt induction led to cell
death [25]. The reasons for these discrepancies are unclear, but may
be attributable to the cell-line models used, different dosing regimens
and additional non-specific effects of chemical Wnt modulators.
Consistent with this previous report, however, we did observe MYCN
and Wnt interaction, although the genes we show to be MYCN
repressed have not previously been demonstrated to be MYCN-
regulated.
Whilst the differentiating effects of Wnt ligands may be significant
for potential differentiation therapies, the proliferative effect seen with
SK-N-AS cells underlines the need for further delineation of the
genotypes and transcriptional/signalling contexts determining Wnt
responses. SK-N-AS cells are also known to be resistant to ATRA-
mediated differentiation [68]. As well as having mutant NRAS, SK-
N-AS cells have been shown to be dependent on Taz for proliferation
[69]; as both Ras and Hippo-Yap/Taz can associate with Wnt
signalling, we examined Ras activity and Taz protein levels in SK-N-
AS cells after Wnt induction, but did not observe any differences
(data not shown). Two recent studies have shown that SK-N-AS cells
have a transcriptional context that is quite different from most
neuroblastoma cell lines [4,5], with the first of these dividing
neuroblastoma cells into mesenchymal (MES) or adrenergic (ADRN)
types. Our analysis of another MES line, GI-MEN, did not however
support the notion that induction of proliferation by Wnt is solely
attributable to a MES identity. We have previously shown that SK-N-
AS cells are also quite different from SK-N-BE(2)-C and SH-SY5Y
cells in terms of their genome-wide DNA methylation pattern [70],
and the epigenetic identity of SK-N-AS has been shown to influence
their differentiation response [28,71]. Thus further analysis at the
epigenetic and proteomic level with a broad range of neuroblastoma
cell lines will be necessary to precisely identify the determinants of the
phenotypic responses to Wnt signalling by neuroblastoma cells.
To date, several studies have proposed that elevated expression of
Wnt/β-catenin target genes can be used to derive a prognostic
signature indicative of poor prognosis in neuroblastoma [24,25,50].
However, analysis of primary tumour datasets shows that expression
of our bona fide Wnt gene set, which has essentially no overlap with
gene sets used in the other studies, reveals a much more complex
picture, with expression patterns varying in four distinct patient
cohorts. Low expression of the metagene WMG-2 is a strong
indicator of poor survival and conversely elevated expression of
WMG-3 is associated with poor prognosis, and is particularly high in
the predominantly MNA cohort. Importantly, both WMG-2 and
WMG-3 identify patients at greater risk despite being classified as low
risk patients, with WMG-2 showing consistent and robust statistical
significance across neuroblastoma expression datasets. Remarkably,
although Asgharzadeh et al. suggested that high expression of a Wnt
signature (based on existing non-neuroblastoma Wnt datasets) is
associated with poor prognosis, we found that WMG-2 shows quite
the opposite trend, and in fact has a striking positive correlation with
the powerful Asgharzadeh signature, whose low expression correlates
with poor prognosis in non-MNA neuroblastoma [50]. This further
underlines the value of our empirically determined neuroblastomaWnt target gene set. Whilst evaluation of the power and utility of
Wnt signatures for prognosis is beyond the scope of this study, further
determination of Wnt target genes in neuroblastoma models may
yield powerful prognostic signatures.
The inference from our work that Wnt signalling may have a pro-
differentiation and tumour suppressive influence is supported by the
recent identification of Wnt pathway mutations in neuroblastoma,
which include probable loss of function mutations of LEF1 and
VANGL1 [20]. Comparison of our 90 DEGs with mutations
identified in this study further revealed that 9 of our Wnt targets
(10%) also exhibited mutations in neuroblastoma; these included
ADAMTS14, AXIN2, CACHD1, DUSP4, IRF2BP2, NPY2R,
NRP2, OPRM1, and ZNRF3. In addition, LGR5 was also mutated
in one sample, adding to the previously reported LGR5 mutations
[13]. Although the pathological consequences of these mutations
remains to be established, these studies, together with ours, suggest
that impairment of Wnt signalling can contribute to neuroblastoma
tumourigenesis.
Numerous regulatory pathways that likely interact/crosstalk with
Wnt/β-catenin signalling emerged through correlation analyses of our
Wnt metagenes. WMG-2 genes, which appear to be down-regulated
in MNA tumours, could be derepressed after MYCN knockdown in
SK-N-BE(2)-C cells, suggesting they are direct targets of MYCN. An
inverse correlation ofMYCN and EPAS1 was suggested recently [28],
and consistent with this EPAS1 increased after MYCN knockdown
(Figure 5). The largest change observed was doublecortin-like kinase
3 (DCLK3), and although the functions of DCLK3 are not
characterised, we note that its paralogue DCLK1 has been shown
to be vital in neuronal migration and axon outgrowth [72]. This is in
keeping with the overall trend for WMG-2 to correlate with neuron
differentiation and axonogenesis, and its associated pathways,
including Hedgehog [54] and Rho-GTPase activation [65]. Notably,
genes encoding regulators of Rac/Rho signalling, were reported to be
mutated in a whole-genome sequencing analysis of 87 neuroblasto-
mas, including one of our WMG-2 genes DLC1 (Deleted In Liver
Cancer 1/ARHGAP7) [73]. Together this suggests that loss of Wnt
stimulation of Rac/Rho signalling (via MYCN-mediated repression)
adds to the mutational disruption of neuritogenesis.
Another key factor that may underlie the expression patterns we
observe in primary tumours is the tumour microenvironment. For
example, Schwannian stroma is associated with better prognosis of
neuroblastoma [51] and can induce differentiation of neuroblasts
[74]. Our immunohistochemistry indicates that well-differentiated/
differentiating tumours have high levels of β-catenin in the
Schwannian stroma, and it is therefore tempting to speculate that
Wnt signalling may induce paracrine differentiating factors such as
BMP4 and Wnt11 to prompt differentiation of neuroblast cells by
Schwann cells. Our future work will aim to investigate this possibility
and further dissect the complex signalling crosstalk in neuroblastoma
using co-culture organoid systems and in vivo models.
Conclusion
Our study reveals that Wnt signalling can promote differentiation of
neuroblastoma via orchestrating a myriad of transcriptional and
signalling nodes, and suggest that Schwannian stroma may be a source
of differentiation signals. Therefore highly specific Wnt small
molecule agonists may have utility in differentiation therapies for
neuroblastoma in the future. However, our data also underlines the
problems of cellular heterogeneity in neuroblastoma, with SK-N-AS
Neoplasia Vol. 20, No. 4, 2018 Wnt Signalling in Neuroblastoma Szemes et al. 349cells proliferating rather than differentiating. The challenge of
defining critical regulatory circuits controlling differentiation in the
context of the genetic and signalling heterogeneity of neuroblastoma
is immense, but our study emphasises that Wnt signalling is one of
the key players.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.01.009.
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